Trial Profile
A Phase I Trial of Dasatinib in Combination With Crizotinib in Patients With Advanced Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Crizotinib (Primary) ; Dasatinib (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; Bone metastases; Cervical cancer; Colorectal cancer; Fallopian tube cancer; Gastrointestinal stromal tumours; Glioblastoma; Head and neck cancer; Liver cancer; Lung cancer; Lymphoma; Malignant melanoma; Malignant thymoma; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours; Uterine cancer
- Focus Adverse reactions
- 12 Jul 2019 Status changed from active, no longer recruiting to completed.
- 19 Oct 2017 Results published in the Investigational New Drugs
- 28 Sep 2017 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2019.